Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 2 7Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Glioblastoma 2Colorectal Neoplasms 2Advanced Malignancies 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Recurrent Squamous Cell Carcinoma of Head 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × cemiplimab × Clear all
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT03005782 2024-05-01

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Regeneron Pharmaceuticals

Phase 1 Completed
333 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡